{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T20:36:50Z","timestamp":1793738210038,"version":"4.6.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Retin Vitr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Macular edema, a major cause of vision loss in diabetic retinopathy, involves retinal fluid accumulation and retinal thickening due to vascular dysfunction and inflammation. Standard treatments include anti-VEGF agents, corticosteroids, and laser photocoagulation, but limitations such as incomplete response and adverse effects exist. Statins, known for lipid-lowering and pleiotropic anti-inflammatory effects, have emerged as a potential therapeutic option.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a systematic review and meta-analysis registered with PROSPERO (CRD420251082672) following PRISMA guidelines. Peer-reviewed studies evaluating statins\u2019 efficacy and safety in macular edema were identified via multiple databases up to May 2025. Included studies encompassed randomized controlled trials and observational studies involving patients with macular edema treated with statins versus controls. Key outcomes were hard exudate reduction, retinal thickness, visual acuity, diabetic retinopathy progression, and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Ten eligible studies involving atorvastatin and simvastatin showed statins significantly reduced hard exudates (risk ratio 4.42, p=0.03) and retinal thickness, with a 58% reduction in diabetic retinopathy progression. Statins also decreased the need for laser treatment by 32%. Visual acuity improvement was inconsistent, with benefits mainly in dyslipidemic patients. Safety analysis revealed no significant increase in adverse events. Statin effects were more pronounced in patients with elevated lipid levels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Statins demonstrate promising anatomical and preventive benefits in diabetic macular edema, particularly in patients with dyslipidemia, by reducing lipid exudation and stabilizing retinal vasculature. Despite limited visual acuity improvement, their favorable safety profile supports considering statins as adjunctive therapy. Further large-scale, long-term trials are warranted to confirm these findings and optimize treatment protocols.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40942-025-00724-y","type":"journal-article","created":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T11:28:10Z","timestamp":1762255690000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Are statins a promising therapeutic strategy for macular edema? Insights from a systematic review and meta-analysis"],"prefix":"10.1186","volume":"11","author":[{"given":"Kai-Yang","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoi-Chun","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Ming","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,4]]},"reference":[{"key":"724_CR1","doi-asserted-by":"crossref","unstructured":"Coscas G, Cunha-Vaz J, Soubrane G. Macular edema: definition and basic concepts, Dev Ophthalmol, vol. 58, no. 2, pp. 1\u201310, 2017.","DOI":"10.1159\/000455264"},{"key":"724_CR2","doi-asserted-by":"crossref","unstructured":"Spaide RF. Retinal vascular cystoid macular edema: review and new theory, Retina, vol. 36, no. 10, pp. 1823\u20131842, 2016.","DOI":"10.1097\/IAE.0000000000001158"},{"key":"724_CR3","doi-asserted-by":"crossref","unstructured":"Scholl S, Kirchhof J, Augustin AJ. Pathophysiology of macular edema, Ophthalmologica, vol. 224, no. Suppl. 1, pp. 8\u201315, 2010.","DOI":"10.1159\/000315155"},{"key":"724_CR4","first-page":"1128811","volume":"10","author":"CD Haydinger","year":"2023","unstructured":"Haydinger CD, Ferreira LB, Williams KA, Smith JR. Mech Macular Edema Front Med. 2023;10:1128811.","journal-title":"Mech Macular Edema Front Med"},{"key":"724_CR5","doi-asserted-by":"crossref","unstructured":"Fardeau C, Champion E, Massamba N, LeHoang P. Uveitic macular edema, Eye, vol. 30, no. 10, pp. 1277\u20131292, 2016.","DOI":"10.1038\/eye.2016.115"},{"key":"724_CR6","doi-asserted-by":"crossref","unstructured":"Zur D, Fischer N, Tufail A, Mon\u00e9s J, Loewenstein A. Postsurgical cystoid macular edema, European Journal of Ophthalmology, vol. 21, no. 6_suppl, pp. 62\u201368, 2011.","DOI":"10.5301\/EJO.2010.6058"},{"key":"724_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40662-015-0026-2","volume":"2","author":"R Lee","year":"2015","unstructured":"Lee R, Wong TY, Sabanayagam C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye Vis. 2015;2:1\u201325.","journal-title":"Eye Vis"},{"key":"724_CR8","doi-asserted-by":"crossref","unstructured":"Scholl S, Augustin A, Loewenstein A, Rizzo S, Kuppermann BD. General pathophysiology of macular edema, Eur J Ophthalmol, vol. 21, no. 6_suppl, pp. 10\u201319, 2011.","DOI":"10.5301\/EJO.2010.6050"},{"issue":"3","key":"724_CR9","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1007\/s00431-022-04782-4","volume":"182","author":"S Cohen","year":"2023","unstructured":"Cohen S, et al. Ocular injury from foam dart (Nerf) blasters: a case series. Eur J Pediatrics. 2023;182(3):1099\u2013103.","journal-title":"Eur J Pediatrics"},{"key":"724_CR10","doi-asserted-by":"publisher","unstructured":"Zhou Q, Liao J. Statins and Cardiovascular Diseases: from cholesterol lowering to pleiotropy, Curr Pharm Des., vol. 15, no. 5, pp. 467\u2013478, 2009, https:\/\/doi.org\/10.2174\/138161209787315684","DOI":"10.2174\/138161209787315684"},{"key":"724_CR11","doi-asserted-by":"publisher","unstructured":"Oesterle A, Laufs U, Liao JK. Pleiotropic effects of statins on the cardiovascular system, circulation research, vol. 120, no. 1, pp. 229\u2013243, 2017, https:\/\/doi.org\/10.1161\/circresaha.116.308537","DOI":"10.1161\/circresaha.116.308537"},{"key":"724_CR12","doi-asserted-by":"publisher","DOI":"10.1055\/a-1873-1978","author":"R Wasim","year":"2022","unstructured":"Wasim R, et al. Pleiotropic benefits of Statins in cardiovascular diseases. Drug Res. 2022. https:\/\/doi.org\/10.1055\/a-1873-1978.","journal-title":"Drug Res"},{"key":"724_CR13","doi-asserted-by":"crossref","unstructured":"Cheema AA, Cheema HR, Cheema R. Diabetic macular edema management: a review of anti-Vascular Endothelial Growth Factor (VEGF) therapies, Cureus, vol. 16, no. 1, 2024.","DOI":"10.7759\/cureus.52676"},{"issue":"1","key":"724_CR14","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1080\/17469899.2024.2402991","volume":"20","author":"M Kalavar","year":"2025","unstructured":"Kalavar M, Sridhar J. Recent advances in ocular injectables for age-related macular degeneration, diabetic macular edema, and macular edema due to retinal vein occlusion. Expert Rev Ophthalmol. 2025;20(1):29\u201339.","journal-title":"Expert Rev Ophthalmol"},{"key":"724_CR15","doi-asserted-by":"crossref","unstructured":"Ruiz-Medrano J, Gonzalez-Buendia L, Ruiz-Moreno JM. When to perform a treatment switch in diabetic macular edema in patients with inadequate response to anti-VEGF. Med Res Arc., 10, 5, 2022.","DOI":"10.18103\/mra.v10i5.2741"},{"key":"724_CR16","doi-asserted-by":"crossref","unstructured":"Falavarjani KG, Nguyen QD. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature, Eye, 27, 7, pp. 787\u201394, 2013.","DOI":"10.1038\/eye.2013.107"},{"key":"724_CR17","doi-asserted-by":"crossref","unstructured":"Sheppard JD, Comstock TL, Cavet ME. Impact of the topical ophthalmic corticosteroid Loteprednol etabonate on intraocular pressure, Adv in ther, 33, pp. 532\u201352, 2016.","DOI":"10.1007\/s12325-016-0315-8"},{"key":"724_CR18","doi-asserted-by":"crossref","unstructured":"Nozaki M, Ando R, Kimura T, Kato F, Yasukawa T. The role of laser photocoagulation in treating diabetic macular edema in the era of intravitreal drug administration: a descriptive review, medicina, 59, 7, p. 1319, 2023.","DOI":"10.3390\/medicina59071319"},{"issue":"2","key":"724_CR19","first-page":"216","volume":"4","author":"T Shiraya","year":"2011","unstructured":"Shiraya T, Kato S, Shigeeda T, Fukushima H. Vitreous hemorrhage and fibrovascular proliferation after laser-induced chorioretinal venous anastomosis. Int J Ophthalmol. 2011;4(2):216.","journal-title":"Int J Ophthalmol"},{"issue":"5","key":"724_CR20","first-page":"328","volume":"22","author":"R Balasubramanian","year":"2021","unstructured":"Balasubramanian R, Maideen NMP. HMG-CoA reductase inhibitors (statins) and their drug interactions involving CYP enzymes, P-glycoprotein and OATP transporters-an overview. Curr Drug Metab. 2021;22(5):328\u201341.","journal-title":"Curr Drug Metab"},{"key":"724_CR21","unstructured":"Al-Saadawi AAA. Modern principles of using inhibitors of the HMG-CoA reductase (statins) in the practice of the clinical hospital, 2023."},{"key":"724_CR22","doi-asserted-by":"crossref","unstructured":"Sharpton SR, Loomba R. Emerging role of Statin therapy in the prevention and management of cirrhosis, portal hypertension, and HCC, hepatology, 78, 6, pp. 1896\u2013906, 2023.","DOI":"10.1097\/HEP.0000000000000278"},{"issue":"1","key":"724_CR23","doi-asserted-by":"publisher","first-page":"pp40","DOI":"10.21608\/odr.2025.347446.1046","volume":"6","author":"AA Zarief","year":"2025","unstructured":"Zarief AA. Pleiotropic effect of statins: beyond cholesterol reduction. Octahedron Drug Res. 2025;6(1):pp40\u201349.","journal-title":"Octahedron Drug Res"},{"key":"724_CR24","doi-asserted-by":"crossref","unstructured":"Satny M, Hubacek JA, Vrablik M. Statins and inflammation, cur Atherosclerosis Rep, 23, pp. 1\u20138, 2021.","DOI":"10.1007\/s11883-021-00977-6"},{"issue":"7","key":"724_CR25","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1002\/jat.4094","volume":"41","author":"D Dymkowska","year":"2021","unstructured":"Dymkowska D, Wrzosek A, Zab\u0142ocki K. Atorvastatin and Pravastatin stimulate nitric oxide and reactive oxygen species generation, affect mitochondrial network architecture and elevate nicotinamide N-methyltransferase level in endothelial cells. J Appl Toxicol. 2021;41(7):1076\u201388.","journal-title":"J Appl Toxicol"},{"key":"724_CR26","doi-asserted-by":"crossref","unstructured":"P\u0142o\u0144ski A et al. The metabolism of big endothelin-1 axis and lipids affects carotid atherosclerotic plaque stability\u2013the possible opposite effects of treatment with statins and aspirin. Pharmacol Rep, pp. 1\u201312, 2025.","DOI":"10.1007\/s43440-025-00714-9"},{"issue":"3","key":"724_CR27","doi-asserted-by":"publisher","first-page":"458","DOI":"10.3390\/jcm10030458","volume":"10","author":"M Mrugacz","year":"2021","unstructured":"Mrugacz M, Bryl A, Zorena K. Retinal vascular endothelial cell dysfunction and neuroretinal degeneration in diabetic patients. J Clin Med. 2021;10(3):458.","journal-title":"J Clin Med"},{"issue":"10","key":"724_CR28","doi-asserted-by":"publisher","first-page":"103320","DOI":"10.1016\/j.drudis.2022.07.005","volume":"27","author":"F Zahedipour","year":"2022","unstructured":"Zahedipour F, Butler AE, Rizzo M, Sahebkar A. Statins and angiogenesis in non-cardiovascular diseases. Drug Discovery Today. 2022;27(10):103320.","journal-title":"Drug Discovery Today"},{"issue":"7","key":"724_CR29","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1515\/revneuro-2023-0005","volume":"34","author":"A Rajabian","year":"2023","unstructured":"Rajabian A, McCloskey AP, Jamialahmadi T, Moallem SA, Sahebkar A. A review on the efficacy and safety of lipid-lowering drugs in neurodegenerative disease. Rev Neurosci. 2023;34(7):801\u201324.","journal-title":"Rev Neurosci"},{"key":"724_CR30","unstructured":"Stewart JM, Coassin M, Schwartz DM. Diabetic Retinopathy, Nih.gov, 2017. [Online]. Available: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK278967\/"},{"key":"724_CR31","doi-asserted-by":"publisher","unstructured":"Chung Y-R, et al. Association of statin use and hypertriglyceridemia with diabetic macular edema in patients with type 2 diabetes and diabetic retinopathy. Cardiovasc Diabetol. 2017;16(1). https:\/\/doi.org\/10.1186\/s12933-016-0486-2.","DOI":"10.1186\/s12933-016-0486-2"},{"key":"724_CR32","doi-asserted-by":"publisher","unstructured":"Page MJ et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews, Systematic Reviews, vol. 10, no. 1, 2021, https:\/\/doi.org\/10.1186\/s13643-021-01626-4","DOI":"10.1186\/s13643-021-01626-4"},{"key":"724_CR33","doi-asserted-by":"publisher","unstructured":"Methley AM, Campbell S, Chew-Graham C, McNally R, Cheraghi-Sohi S. PICO, PICOS and SPIDER: a comparison study of specificity and sensitivity in three search tools for qualitative systematic reviews. BMC Health Serv Res. 2014;14(1). https:\/\/doi.org\/10.1186\/s12913-014-0579-0.","DOI":"10.1186\/s12913-014-0579-0"},{"issue":"1","key":"724_CR34","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1001\/archophthalmol.2010.318","volume":"129","author":"R Klein","year":"2011","unstructured":"Klein R. Prevalence of Age-Related macular degeneration in the US population. Arch Ophthalmol. 2011;129(1):75. https:\/\/doi.org\/10.1001\/archophthalmol.2010.318.","journal-title":"Arch Ophthalmol"},{"key":"724_CR35","doi-asserted-by":"publisher","unstructured":"McGuinness LA. Riskofbias VISualization (robvis): an R package and Shiny web app for visualizing riskofbias assessments, Res Syn Meth, vol. n\/a, no. n\/a, 2020, https:\/\/doi.org\/10.1002\/jrsm.1411","DOI":"10.1002\/jrsm.1411"},{"key":"724_CR36","doi-asserted-by":"crossref","unstructured":"Clarke V, Braun V. Thematic analysis, J Posit Psychol, vol. 12, no. 3, pp. 297\u2013298, 2017.","DOI":"10.1080\/17439760.2016.1262613"},{"issue":"4","key":"724_CR37","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.ajo.2003.11.017","volume":"137","author":"A Gupta","year":"2004","unstructured":"Gupta A, Gupta V, Thapar S, Bhansali A. Lipid-lowering drug Atorvastatin as an adjunct in the management of diabetic macular edema. Am J Ophthalmol. 2004;137(4):675\u201382. https:\/\/doi.org\/10.1016\/j.ajo.2003.11.017.","journal-title":"Am J Ophthalmol"},{"key":"724_CR38","doi-asserted-by":"publisher","unstructured":"Panagiotoglou TD et al. Atorvastatin for diabetic macular edema in patients with diabetes mellitus and elevated serum cholesterol, Ophthalmic Sur, Lasers and Imaging Retina, 41, 3, pp. 316\u201322, 2010, https:\/\/doi.org\/10.3928\/15428877-20100430-04","DOI":"10.3928\/15428877-20100430-04"},{"issue":"2","key":"724_CR39","doi-asserted-by":"publisher","first-page":"175","DOI":"10.18231\/2395-1451.2018.0039","volume":"4","author":"A Bhatti","year":"2020","unstructured":"Bhatti A, Narang S. Effect of Atorvastatin on hard exudates in type 2 diabetic patients with normal lipid profile. Indian J Clin Experimental Ophthalmol. 2020;4(2):175\u20137. https:\/\/doi.org\/10.18231\/2395-1451.2018.0039.","journal-title":"Indian J Clin Experimental Ophthalmol"},{"key":"724_CR40","doi-asserted-by":"publisher","unstructured":"Sen K, Misra A, Kumar A, Pandey RM. Simvastatin retards progression of retinopathy in diabetic patients with hypercholesterolemia, Diabetes Res and Cli Prac, vol. 56, no. 1, pp. 1\u201311, 2002, https:\/\/doi.org\/10.1016\/s0168-8227(01)00341-2","DOI":"10.1016\/s0168-8227(01)00341-2"},{"issue":"1","key":"724_CR41","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3126\/nepjoph.v4i1.5846","volume":"4","author":"S Narang","year":"1970","unstructured":"Narang S, Sood S, Kaur B, Singh R, Malik A, Kaur J. Atorvastatin in clinically-significant macular edema in diabetics with a normal lipid profile. Nepal J Ophthalmol. 1970;4(1):23\u20138. https:\/\/doi.org\/10.3126\/nepjoph.v4i1.5846.","journal-title":"Nepal J Ophthalmol"},{"issue":"6","key":"724_CR42","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1056\/nejmoa0706245","volume":"358","author":"P G\u00e6de","year":"2008","unstructured":"G\u00e6de P, Lund-Andersen H, Parving H-H, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358(6):580\u201391. https:\/\/doi.org\/10.1056\/nejmoa0706245.","journal-title":"N Engl J Med"},{"key":"724_CR43","doi-asserted-by":"publisher","unstructured":"Miljanovic B, Glynn RJ, Nathan DM, Manson JE, Schaumberg DA. A prospective study of serum lipids and risk of diabetic macular edema in type 1 diabetes, Diabetes, 53, 11, pp. 2883\u201392, 2004, https:\/\/doi.org\/10.2337\/diabetes.53.11.2883","DOI":"10.2337\/diabetes.53.11.2883"},{"key":"724_CR44","doi-asserted-by":"publisher","DOI":"10.2174\/138920111794480570","author":"J-C Ansquer","year":"2011","unstructured":"Ansquer J-C, Crimet DC, Foucher C. Fibrates and Statins in the treatment of diabetic retinopathy. Ingenta Connect. 2011. https:\/\/doi.org\/10.2174\/138920111794480570.","journal-title":"Ingenta Connect"},{"key":"724_CR45","doi-asserted-by":"publisher","unstructured":"Ucgun NI, Yildirim Z, Kilic N, Gursel E. The importance of serum lipids in exudative diabetic macular edema in type 2 diabetic patients. Ann NY Acad Sci, 1100, 1, pp. 213\u20137, 2007, https:\/\/doi.org\/10.1196\/annals.1395.021","DOI":"10.1196\/annals.1395.021"}],"container-title":["International Journal of Retina and Vitreous"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-025-00724-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40942-025-00724-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-025-00724-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T22:29:07Z","timestamp":1762295347000},"score":1,"resource":{"primary":{"URL":"https:\/\/journalretinavitreous.biomedcentral.com\/articles\/10.1186\/s40942-025-00724-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,4]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["724"],"URL":"https:\/\/doi.org\/10.1186\/s40942-025-00724-y","relation":{},"ISSN":["2056-9920"],"issn-type":[{"value":"2056-9920","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,4]]},"assertion":[{"value":"8 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This study does not involve human participants, human data, or human tissue.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. This study does not include individual data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"CRD420251082672.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"PROSPERO number"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"122"}}